Reduction Of Proteinuria In Patients With Diabetes Mellitus Type 2 With Empagliflozin Treatment

Abstract

Empagliflozin belongs to the group of SGLT2 inhibitors, which are a new class of glucose lowering agents. Through their unique mechanism to reduce sodium and glucose reabsorption through the proximal tubule, SGLT2 inhibitors play an important role in the prevention and treatment of diabetic nephropathy. The study included 8 patients with type 2 diabetes mellitus on empagliflozin therapy. All of them had their first morning urine albumin/creatinine ratios examined at the beginning and at the third month of treatment. The results showed a significant decrease in albuminuria in 6 of the patients by the third month after applying empagliflozin.